Table 2. Comparison of endovascular treatment data and study endpoints within 30 days and 90 days after intervention of patients receiving low-dose aspirin and patients receiving high-dose aspirin*.
| Patients receiving low-dose aspirin (N = 273) | Patients receiving high-dose aspirin (N = 97) | P value | |
| Endovascular treatment methods — no. (%) | |||
| Balloon-mounted stenting | 159 (58.2) | 63 (64.9) | 0.28 |
| Balloon angioplasty + expendable stenting | 89 (32.6) | 24 (24.7) | 0.16 |
| Balloon angioplasty | 22 (8.1) | 6 (6.2) | 0.66 |
| Failure | 3 (1.0) | 4 (4.1) | 0.08 |
| Multi vessels treated — no. (%) | 13 (4.8) | 3 (3.1) | 0.77 |
| Loss of follow-up — no. (%) | 6 (2.2) | 4 (4.1) | 0.30 |
| Dual Antiplatelet drugs use within 90 days — no. (%) | 270 (98.9) | 96 (98.9) | 1.00 |
| Study endpoints within 30 days — no. (%) | |||
| Acute thrombosis | 4 (1.5) | 0 (0) | 0.58 |
| Subacute thrombosis | 5 (1.8) | 2 (2.1) | 1.00 |
| Thrombosis | 9 (3.3) | 2 (2.1) | 0.74 |
| Ischaemic stroke | 10(3.7) | 4 (4.1) | 0.77 |
| Hemorrhagic stroke | 3 (1.1) | 1 (1.0) | 1.00 |
| Death | 1 (0.4) | 2 (2.1) | 0.17 |
| Non-stroke hemorrhage | 1(0.4) | 1 (1.0) | 0.46 |
| Hyperperfusion symptoms | 9 (3.3) | 5 (5.2) | 0.54 |
| Study endpoints within 90 days — no. (%) | |||
| Ischaemic stroke | 14 (5.1) | 5 (5.2) | 1.00 |
| Hemorrhagic stroke | 3 (1.1) | 1 (1.0) | 1.00 |
| Death | 2 (0.7) | 2 (2.1) | 0.28 |
| Non-stroke hemorrhage | 2 (0.7) | 1 (1.0) | 1.00 |
*Plus–minus values are means ±SD. Baseline characteristics of the two groups were compared with the use of either an independent groups t-test (for means) or a chi-square test (for percentages).